Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

@article{Fiorentino2013MostPW,
  title={Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.},
  author={David F. Fiorentino and Lorinda S Chung and Lisa Christopher-Stine and Lisa C. Zaba and Shufeng Li and Andrew Mammen and Antony Rosen and Livia A. Casciola-Rosen},
  journal={Arthritis and rheumatism},
  year={2013},
  volume={65 11},
  pages={2954-62}
}
OBJECTIVE Since dermatomyositis (DM) is associated with an increased risk of malignancy, accurate identification of patients likely to harbor cancers is important. Using immunoprecipitations from radiolabeled cell lysates, several groups recently showed that anti-transcription intermediary factor 1γ (anti-TIF-1γ) antibodies are associated with malignancy in DM. We undertook this study to develop sensitive, specific assays to detect antibodies against TIF-1γ and nuclear matrix protein NXP-2 and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…